BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30635633)

  • 1. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
    Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
    Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.
    Tejedor JR; Bueno C; Vinyoles M; Petazzi P; Agraz-Doblas A; Cobo I; Torres-Ruiz R; Bayón GF; Pérez RF; López-Tamargo S; Gutierrez-Agüera F; Santamarina-Ojeda P; Ramírez-Orellana M; Bardini M; Cazzaniga G; Ballerini P; Schneider P; Stam RW; Varela I; Fraga MF; Fernández AF; Menéndez P
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Prieto C; López-Millán B; Roca-Ho H; Stam RW; Romero-Moya D; Rodríguez-Baena FJ; Sanjuan-Pla A; Ayllón V; Ramírez M; Bardini M; De Lorenzo P; Valsecchi MG; Stanulla M; Iglesias M; Ballerini P; Carcaboso ÁM; Mora J; Locatelli F; Bertaina A; Padilla L; Rodríguez-Manzaneque JC; Bueno C; Menéndez P
    Leukemia; 2018 Mar; 32(3):633-644. PubMed ID: 28943635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get?
    Menendez P; Bueno C
    Leuk Res; 2011 Aug; 35(8):989-90. PubMed ID: 21492935
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype.
    Schwartz S; Rieder H; Schläger B; Burmeister T; Fischer L; Thiel E
    Leukemia; 2003 Aug; 17(8):1589-95. PubMed ID: 12886247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements.
    Behm FG; Smith FO; Raimondi SC; Pui CH; Bernstein ID
    Blood; 1996 Feb; 87(3):1134-9. PubMed ID: 8562939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of NG2-positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia.
    Zerkalenkova E; Mikhaylova E; Lebedeva S; Illarionova O; Baidun L; Kashpor S; Osipova E; Maschan M; Maschan A; Novichkova G; Olshanskaya Y; Popov A
    Genes Chromosomes Cancer; 2021 Feb; 60(2):88-99. PubMed ID: 33135273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
    Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
    PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
    Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin enhances the efficacy of cytarabine
    Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
    Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphoblastic leukemia with mature B-cell phenotype in infancy.
    Frater JL; Batanian JR; O'Connor DM; Grosso LE
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):672-7. PubMed ID: 15454841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.
    Tomizawa D; Koh K; Hirayama M; Miyamura T; Hatanaka M; Saikawa Y; Ishii E
    Pediatr Blood Cancer; 2009 Jul; 52(7):808-13. PubMed ID: 19229974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
    Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23.
    Smith FO; Rauch C; Williams DE; March CJ; Arthur D; Hilden J; Lampkin BC; Buckley JD; Buckley CV; Woods WG; Dinndorf PA; Sorensen P; Kersey J; Hammond D; Bernstein ID
    Blood; 1996 Feb; 87(3):1123-33. PubMed ID: 8562938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies.
    Emerenciano M; Renaud G; Sant'Ana M; Barbieri C; Passetti F; Pombo-de-Oliveira MS;
    Leuk Res; 2011 Aug; 35(8):1001-7. PubMed ID: 21444110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
    Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB
    Br J Cancer; 2020 Sep; 123(5):742-751. PubMed ID: 32536690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
    Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
    Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
    Chan WK; Kung Sutherland M; Li Y; Zalevsky J; Schell S; Leung W
    Clin Cancer Res; 2012 Nov; 18(22):6296-305. PubMed ID: 23014531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.